• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Cutaneous alpha‐synuclein deposition in postural tachycardia patients 25th March 2021

godlovesatrier

Senior Member
Messages
2,545
Location
United Kingdom
Cutaneous alpha‐synuclein deposition in postural tachycardia patients
25th March 2021
https://onlinelibrary.wiley.com/doi/10.1002/acn3.51347

Authors

Todd D. Levine, Bailey Bellaire, Christopher Gibbons, Roy Freeman


Objective
To report a case series of patients with neuropathic POTS and cutaneous phosphorylated alpha‐synuclein (P‐SYN) deposition on skin biopsy and compare these to neuropathic POTS patients without P‐SYN deposition.

Of 296 patients seen with POTS, 22 patients with suspected neuropathic POTS had skin biopsies performed during their evaluation. Seven of 22 patients had P‐SYN present on skin biopsy, while 15 individuals did not. Those with P‐SYN on biopsy: (1) were more likely to be male; (2) had features of REM sleep behavioral disorder; (3) reported less sleepiness and cognitive impairment; and (4) noted greater symptoms of gastroparesis. On autonomic testing, the group with P‐SYN deposition was more likely to have a hypertensive response to tilt‐table testing and abnormal QSART responses.
 
Last edited:

godlovesatrier

Senior Member
Messages
2,545
Location
United Kingdom
According to twitter they've found alpha synuclein in most pots patients and it's linked to a variety of other diseases. But someone on twitter also said the study has flaws.

Re-reading the study results it sounds like a possibly POTS subset.
 
Last edited:

pattismith

Senior Member
Messages
3,931
the question it raises would be, these 30% of POTS patients with P-Syn in their skin autonomic nerves...Do they have an already known alpha‐synucleinopathies, or do they have another one that is not yet identified?


Results
Of 296 patients seen with POTS, 22 patients with suspected neuropathic POTS had skin biopsies performed during their evaluation.

Seven of 22 patients had P‐SYN present on skin biopsy, while 15 individuals did not.

Those with P‐SYN on biopsy: (1) were more likely to be male; (2) had features of REM sleep behavioral disorder; (3) reported less sleepiness and cognitive impairment; and (4) noted greater symptoms of gastroparesis.

On autonomic testing, the group with P‐SYN deposition was more likely to have a hypertensive response to tilt‐table testing and abnormal QSART responses.
1617019898457.png


The intra‐epidermal nerve fiber density (IENFD) was similar in those with and without P‐syn, although there was a trend for those with P‐syn on biopsy to have skin biopsy results consistent with a small fiber neuropathy (4/7 cases had reduced IENFD) versus those with normal synuclein staining in whom only 2/15 had reduced IENFD (p = 0.08).

There were significant differences in sympathetic cholinergic function, as measured by QSART.
In the group without P‐syn, 2/15 patients had one or more reduced QSART responses.
In contrast, the group with abnormal P‐syn had 6/7 patients with at least one abnormal QSART response (p < 0.05, Fishers exact test)
note:
The quantitative sudomotor axon reflex test (QSART, or sweat test) measures the nerves that control sweating.
 

Celandine

Senior Member
Messages
201
Well, it's not 30% of POTS patients. It was a study with 296 participants and then of those 22 with suspected neuropathic POTS were given skin biopsies and 7 of those tested positive for P-SYN. Would be very interesting to see what the results would be if all 296 were tested. By choosing those particular patients out of the cohort they skewed strongly in favour of the positive result.